tislelizUMaB in canceR Patients With molEcuLar residuaL Disease

"Formulation : 100 mg of antibody in 10 mL of isotonic solution (25 mM citrate buffer, 15 mM L-histidine/histidine hydrochloride, 190 mM trehalose-dihydrate, and 0.02% polysorbate 20 at pH 6.5) in a single-use vial.~Dose Regimen: Tislelizumab 400 mg every 6 weeks (Q6W) for a maximum of 9 cycles, on the first day of each cycle, in IV."

Blood sampling for analyses of MRD (Molecular Residual Disease)

"Pharmaceutical form : Solvent IV bags used for dilution of tislelizumab (for example: CHLORURE DE SODIUM FRESENIUS 0,9 %, solution injectable) Dose Regimen: every 6 weeks (Q6W) for a maximum of 9 cycles, on the first day of each cycle, in IV."